Title: Effects of endoscopic injection sclerotherapy for esophagogastric varices on portal
hemodynamics and liver function
Version: 2 Date: 01 Feb 2022
Reviewer:  Xiaoquan Huang
Reviewer's report:
This study focus on the topic that which group of cirrhotic patients should receive sclerotherapy,
while it is not recommended in the guideline. However, there is a lot to be clarified.
Is it a prospective study? There is a lot of patients excluded because of the lack of Xe-CT. Please
provided the registered number of the trial.
How to define recurrence? As for cirrhotic patients with EGV, endpoint including death, re-
bleeding should be evaluated.
Although albumin and prothrombin time were observed improved after endoscopic injection
sclerotherapy, however, there is no effect on the overall survival and the recurrence of varices.
This might be contribute to the significant difference between age, sex, ICG15, etc. which lead
to the low reliability of this study
The sample size is quite small.
Title: Effects of endoscopic injection sclerotherapy for esophagogastric varices on portal
hemodynamics and liver function
Version: 2 Date: 01 Feb 2022
Reviewer:  Xiaoquan Huang
Reviewer's report:
This study focus on the topic that which group of cirrhotic patients should receive sclerotherapy,
while it is not recommended in the guideline. However, there is a lot to be clarified.
Is it a prospective study? There is a lot of patients excluded because of the lack of Xe-CT. Please
provided the registered number of the trial.
How to define recurrence? As for cirrhotic patients with EGV, endpoint including death, re-
bleeding should be evaluated.
Although albumin and prothrombin time were observed improved after endoscopic injection
sclerotherapy, however, there is no effect on the overall survival and the recurrence of varices.
This might be contribute to the significant difference between age, sex, ICG15, etc. which lead
to the low reliability of this study
The sample size is quite small.
Please review this paper.
user
Title: Effects of endoscopic injection sclerotherapy for esophagogastric varices on portal
hemodynamics and liver function
Version: 2 Date: 01 Feb 2022
Reviewer:  Xiaoquan Huang
Reviewer's report:
This study focus on the topic that which group of cirrhotic patients should receive sclerotherapy,
while it is not recommended in the guideline. However, there is a lot to be clarified.
Is it a prospective study? There is a lot of patients excluded because of the lack of Xe-CT. Please
provided the registered number of the trial.
How to define recurrence? As for cirrhotic patients with EGV, endpoint including death, re-
bleeding should be evaluated.
Although albumin and prothrombin time were observed improved after endoscopic injection
sclerotherapy, however, there is no effect on the overall survival and the recurrence of varices.
This might be contribute to the significant difference between age, sex, ICG15, etc. which lead
to the low reliability of this study
The sample size is quite small.
assistant